Company Overview of Cardio3 BioSciences SA
Cardio3 BioSciences SA, a biopharmaceutical company, discovers, develops, and commercializes regenerative and protective therapies for cardiovascular diseases in Belgium. It provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. The company’s products include C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy; and C3BS-GQR-1, a protein-based product candidate for protecting heart tissue from acute injury and promoting activation of resident cardiac stem cells in an acute myocardial infarction setting. Its preclinical stage products comprise C3BS-GQR-4, a protein based produc...
Rue Edouard Belin 12
Founded in 2004
Key Executives for Cardio3 BioSciences SA
Chief Executive Officer and Executive Director
Total Annual Compensation: $315.0K
Compensation as of Fiscal Year 2013.
Cardio3 BioSciences SA Key Developments
Cardio3 BioSciences Appoints Vincent Brichard as Vice President Immuno-Oncology
Jan 8 15
Cardio3 BioSciences announced the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences. Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels.
Cardio3 BioSciences Announces the Enrolment of the 240th Patient for its Chart-1 Phase III Clinical Trial for the Treatment of Heart Failure
Dec 19 14
Cardio3 BioSciences announced the enrolment of the 240th patient in its CHART-1 European trial for C-Cure®, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. With recruitment that started in mid-2013, Cardio3 BioSciences has enrolled 240 patients in less than 18 months, ahead of schedule. As usual in clinical trials targeting severe indications, the company will continue to recruit additional patients in anticipation of patient dropouts. The CHART-1 trial is currently ongoing in 12 countries in Europe and Israel. The CHART-1 (Congestive Heart failure Cardiopoietic Regenerative Therapy) trial represents the world's first phase III trial for a pre-programmed cellular therapy for the treatment of heart failure.
Cardio3 BioSciences SA Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015
Dec 9 14
Cardio3 BioSciences SA Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015. Venue: Lyon’s Convention Center, Lyon, France. Presentation Date(s): Jan-08-2015. Jan-09-2015.
Similar Private Companies By Industry
Recent Private Companies Transactions